Celltrion Opens Up Canadian Market For Remsima SC

Launches Subcutaneous Version Of Biosimilar Infliximab Rival To Remicade

 
• By Dave Wallace
  
Canada Flag Open Door
Celltrion’s launch opens up the Canadian market for Remsima SC • Source: Alamy

More from Biosimilars

More from Products